{"id":"W1970304552","doi":"10.1097/cmr.0b013e32832bbde6","title":"Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma","year":2009,"lang":"en","type":"article","venue":"Melanoma Research","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Neutropenia; Adverse effect; myalgia; Clinical endpoint; Internal medicine; Toxicity; Melanoma; Dacarbazine; Phases of clinical research; Surgery; Chemotherapy; Gastroenterology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000501784,0.0001791806,0.0002535518,0.0001935469,0.0001074916,0.00001930819,0.0003027315,0.0001026786,0.00009979434],"category_scores_gemma":[0.00001762753,0.0001426458,0.00004385443,0.0003163741,0.0000557367,0.000007146324,0.00009222475,0.0001935366,0.00000394709],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003636677,"about_ca_system_score_gemma":0.0001424188,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007592665,"about_ca_topic_score_gemma":0.0002002191,"domain_scores_codex":[0.9981259,0.0001647576,0.000295248,0.000468995,0.0004868098,0.0004582624],"domain_scores_gemma":[0.9989836,0.00001588963,0.00007536744,0.0005420887,0.0002802483,0.0001028239],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01111456,0.01306537,0.006218335,0.00001466559,0.0001278995,0.00003894757,0.0008184636,0.00001917691,0.80838,0.0002325987,0.00009481582,0.1598752],"study_design_scores_gemma":[0.03160096,0.2346947,0.03331349,0.00004330825,0.000008912486,0.000004243623,0.0008105448,0.00002041364,0.6907457,0.00045282,0.007950588,0.0003543871],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977036,0.0004401816,0.00001867607,0.00009612651,0.00004824735,0.001012421,0.00003161218,0.00000641303,0.0006426827],"genre_scores_gemma":[0.9987493,0.0001014249,0.0001017631,0.0001041892,0.00005792963,0.0000616398,0.00007735081,0.00002681355,0.0007196254],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2216293,"threshold_uncertainty_score":0.5816926,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03306034924672339,"score_gpt":0.3534352690582084,"score_spread":0.320374919811485,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}